Literature DB >> 25609178

HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute interstitial lung disease in clinically amyopathic dermatomyositis patients.

Jing Zou1, Qiang Guo, Jiachang Chi, Huawei Wu, Chunde Bao.   

Abstract

The aim of this study is to evaluate the factors associated to 1-year mortality in clinically amyopathic dermatomyositis (CADM) patients with acute interstitial lung disease (ILD). A single center of 37 cases of Chinese patients with CADM was reviewed retrospectively in Renji hospital. All CADM patients were diagnosed with ILD; there were 24 cases of acute interstitial pneumonia (AIP) and 13 cases of acute exacerbation of non-acute interstitial pneumonia non-AIP. The clinical features, including blood tests, chest high-resolution computed tomography (HRCT) score, and lung function, were analyzed, respectively. Neutrophil lymphocyte ratio (NLR), serum ferritin level, serum lactate dehydrogenase (LDH) level, and HRCT score were statistically significant factors on univariate analysis. Multivariate analysis revealed that the overall HRCT score (HR 1.134, 95 % confidence interval 1.009-1.275, P = 0.017) and serum ferritin level (HR 1.001, 95 % confidence interval 1.002-1.007, P = 0.010) were independently significant factors of 1-year mortality. C statistic value of HRCT score (c statistic value 0.867, P < 0.0001) and serum ferritin level (c statistic value 0.808, P = 0.002) were statistically significant in the classification of non-survivors. Patients with calcineurin inhibitor presented a better outcome than those without calcineurin inhibitor (log-rank test, P = 0.006). HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute ILD in CADM patients. Calcineurin inhibitor might improve the outcome of CADM patients with acute ILD.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25609178     DOI: 10.1007/s10067-015-2866-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  27 in total

1.  Fleischner Society: glossary of terms for thoracic imaging.

Authors:  David M Hansell; Alexander A Bankier; Heber MacMahon; Theresa C McLoud; Nestor L Müller; Jacques Remy
Journal:  Radiology       Date:  2008-01-14       Impact factor: 11.105

2.  Clinically amyopathic dermatomyositis: what can we now tell our patients?

Authors:  Richard D Sontheimer
Journal:  Arch Dermatol       Date:  2010-01

Review 3.  The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination.

Authors:  G R Bernard; A Artigas; K L Brigham; J Carlet; K Falke; L Hudson; M Lamy; J R Legall; A Morris; R Spragg
Journal:  Am J Respir Crit Care Med       Date:  1994-03       Impact factor: 21.405

4.  Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis.

Authors:  Takahisa Gono; Yasushi Kawaguchi; Masako Hara; Ikuko Masuda; Yasuhiro Katsumata; Mikiko Shinozaki; Yuko Ota; Eri Ozeki; Hisashi Yamanaka
Journal:  Rheumatology (Oxford)       Date:  2010-04-12       Impact factor: 7.580

5.  Acute interstitial pneumonia: comparison of high-resolution computed tomography findings between survivors and nonsurvivors.

Authors:  Kazuya Ichikado; Moritaka Suga; Nestor L Müller; Hiroyuki Taniguchi; Yasuhiro Kondoh; Masanori Akira; Takeshi Johkoh; Naoki Mihara; Hironobu Nakamura; Mutsumasa Takahashi; Masayuki Ando
Journal:  Am J Respir Crit Care Med       Date:  2002-06-01       Impact factor: 21.405

6.  Idiopathic inflammatory myopathy with diffuse alveolar damage.

Authors:  C-S Lee; T-L Chen; C-Y Tzen; F-J Lin; M-J Peng; C-L Wu; P-J Chen
Journal:  Clin Rheumatol       Date:  2002-09       Impact factor: 2.980

7.  The prognostic value of HRCT in myositis-associated interstitial lung disease.

Authors:  Kiminobu Tanizawa; Tomohiro Handa; Ran Nakashima; Takeshi Kubo; Yuji Hosono; Kensaku Aihara; Kohei Ikezoe; Kizuku Watanabe; Yoshio Taguchi; Kazuhiro Hatta; Toru Oga; Kazuo Chin; Sonoko Nagai; Tsuneyo Mimori; Michiaki Mishima
Journal:  Respir Med       Date:  2013-02-26       Impact factor: 3.415

8.  Interstitial lung disease in polymyositis and dermatomyositis.

Authors:  I Marie; E Hachulla; P Chérin; S Dominique; P-Y Hatron; M-F Hellot; B Devulder; S Herson; H Levesque; H Courtois
Journal:  Arthritis Rheum       Date:  2002-12-15

9.  Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis.

Authors:  Takuya Kotani; Shigeki Makino; Tohru Takeuchi; Maki Kagitani; Takeshi Shoda; Ayu Hata; Yoko Tabushi; Toshiaki Hanafusa
Journal:  J Rheumatol       Date:  2007-12-15       Impact factor: 4.666

10.  Successful treatment with tacrolimus of progressive interstitial pneumonia associated with amyopathic dermatomyositis refractory to cyclosporine.

Authors:  Masaru Ando; Eishi Miyazaki; Mari Yamasue; Yukiko Sadamura; Toshihiro Ishii; Ryuichi Takenaka; Takeo Ito; Shin-ichi Nureki; Toshihide Kumamoto
Journal:  Clin Rheumatol       Date:  2010-02-04       Impact factor: 3.650

View more
  14 in total

1.  Retrospective study of the clinical characteristics and risk factors of rheumatoid arthritis-associated interstitial lung disease.

Authors:  Yongfeng Zhang; Hongbin Li; Nawei Wu; Xin Dong; Yi Zheng
Journal:  Clin Rheumatol       Date:  2017-02-12       Impact factor: 2.980

Review 2.  Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis.

Authors:  Wanlong Wu; Li Guo; Yakai Fu; Kaiwen Wang; Danting Zhang; Wenwen Xu; Zhiwei Chen; Shuang Ye
Journal:  Clin Rev Allergy Immunol       Date:  2021-01-06       Impact factor: 8.667

3.  18F-FDG PET/CT and HRCT: a combined tool for risk stratification in idiopathic inflammatory myopathy-associated interstitial lung disease.

Authors:  Yuying Zhang; Zhifeng Chen; Yali Long; Bing Zhang; Qiao He; Kejing Tang; Xiangsong Zhang
Journal:  Clin Rheumatol       Date:  2022-06-27       Impact factor: 3.650

4.  A New Predictive Model for the Prognosis of MDA5+ DM-ILD.

Authors:  Qian Niu; Li-Qin Zhao; Wan-Li Ma; Liang Xiong; Xiao-Rong Wang; Xin-Liang He; Fan Yu
Journal:  Front Med (Lausanne)       Date:  2022-06-15

5.  Serum IL8 and mRNA level of CD11b in circulating neutrophils are increased in clinically amyopathic dermatomyositis with active interstitial lung disease.

Authors:  Jing Zou; Jie Chen; Qingran Yan; Qiang Guo; Chunde Bao
Journal:  Clin Rheumatol       Date:  2015-10-12       Impact factor: 2.980

Review 6.  Dermatomyositis Clinical and Pathological Phenotypes Associated with Myositis-Specific Autoantibodies.

Authors:  Paige W Wolstencroft; David F Fiorentino
Journal:  Curr Rheumatol Rep       Date:  2018-04-10       Impact factor: 4.592

Review 7.  Recent Treatment of Interstitial Lung Disease with Idiopathic Inflammatory Myopathies.

Authors:  Hidenaga Kawasumi; Takahisa Gono; Yasushi Kawaguchi; Hisashi Yamanaka
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2015-07-23

8.  Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease.

Authors:  Yasunori Enomoto; Yuzo Suzuki; Hironao Hozumi; Kazutaka Mori; Masato Kono; Masato Karayama; Kazuki Furuhashi; Tomoyuki Fujisawa; Noriyuki Enomoto; Yutaro Nakamura; Naoki Inui; Daisuke Suzuki; Noriyoshi Ogawa; Ran Nakashima; Tsuneyo Mimori; Toshihide Iwashita; Takafumi Suda
Journal:  Arthritis Res Ther       Date:  2017-01-19       Impact factor: 5.156

9.  Noninvasive positive pressure ventilator deteriorates the outcome of pneumomediastinum in anti-MDA5 antibody-positive clinically amyopathic dermatomyositis.

Authors:  Mengmeng Zhou; Yan Ye; Ninghui Yan; Xinyue Lian; Chunde Bao; Qiang Guo
Journal:  Clin Rheumatol       Date:  2020-01-15       Impact factor: 2.980

10.  Myopathy is a Risk Factor for Poor Prognosis of Patients with Systemic Sclerosis: A retrospective cohort study.

Authors:  Meiju Zhou; Lichun Jiang; Liuyan Nie; Ting Chen; Ting Zhang; Wenjia Sun; Joshua Sutikno; Yan Du; Jing Xue
Journal:  Medicine (Baltimore)       Date:  2020-08-14       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.